Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase NA 7Phase 1/2 4Phase 1 4Phase 2/3 3Phase 3 2Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 76Colorectal Neoplasms 55Carcinoma, Hepatocellular 51Stomach Neoplasms 34Colonic Neoplasms 26Breast Neoplasms 23Lung Neoplasms 15Rectal Neoplasms 12Ovarian Neoplasms 12Liver Neoplasms 12Sarcoma 11Gastrointestinal Neoplasms 11Neoplasms 10Esophageal Neoplasms 10Barrett Esophagus 9Melanoma 7Head and Neck Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Prostatic Neoplasms 6Cholangiocarcinoma 6Carcinoma, Renal Cell 5Neoplasm Metastasis 4Colorectal Neoplasms, Hereditary Nonpolyposis 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Pancreatic Ductal Adenocarcinoma 3Osteosarcoma 3Esophageal Squamous Cell Carcinoma 3Disease 3Digestive System Neoplasms 3

Interventions

Interleukin 1 Receptor Antagonist Protein 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pancreatic Adenocarcinoma × Gastrointestinal × Clear all
NCT02550327 2021-06-22

Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer

Baylor Research Institute

Phase EARLY_PHASE1 Completed
20 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡